DGAP-Adhoc

4SC AG: 4SC sells operations of its Discovery division

4SC AG / Key word(s): Disposal/Contract

29.04.2016 13:27

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

4SC sells operations of its Discovery division

Planegg-Martinsried, Germany, 29 April 2016 - 4SC AG (4SC, FSE Prime
Standard: VSC) today announced the sale of the operations of its subsidiary
4SC Discovery GmbH (4SC Discovery) to newly incorporated BioNTech Small
Molecules GmbH (BioNTech Small Molecules). The sale comprises all key
operating assets.

BioNTech Small Molecules is a wholly-owned subsidiary of Mainz,
Germany-based BioNTech AG (BioNTech). The purchase price for the assets to
be transferred with immediate effect amounts to EUR 650 thousand. In
addition and without financial compensation, 4SC will be granted the right
to temporarily utilize research services provided by BioNTech Small
Molecules worth a person year. As of 1 May 2016, all 22 employees of 4SC
Discovery in the framework of a transfer of operations will be taken over
and will continue to work at the existing facility in Planegg-Martinsried.
The assets to be transferred include the 4SCan(R) software developed
in-house for compound discovery and optimization, 4SC Discovery's tangible
fixed assets and its substance libraries. Other intangible assets are not
affected by this transaction.

4SC Discovery will retain its preclinical research projects. 4SC will
continue using the epigenetic schemes and the underlying intellectual
property for itself, and in addition plans to out-license other projects.


---------------------------------------------------------------------------

Information and Explanation of the Issuer to this News:

Enno Spillner, CEO of 4SC, said: 'It is our goal to establish a leading
company in the clinical development of epigenetic anti-cancer drugs. This
is why we are not able to sustainably provide our Discovery division with
the necessary resources required for rapid growth. With the transaction in
effect, it will be possible for us to enhance 4SC cost-efficiently and
focused on its key value drivers. We are very pleased that our long-term
business partner BioNTech can ideally supplement its existing immunotherapy
business and will keep the existing 4SC Discovery facility in Martinsried.'

Dr Sierk Poetting, CFO of BioNTech, added: 'And we are very glad to expand
our team with the experienced and competent scientists of 4SC Discovery.